About
SOLA Biosciences (Boston, MA) is a pre-clinical-stage biopharmaceutical company with a 10-years R&D history, focusing on developing transformative gene-therapies to treat conformational diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and Alzheimer’s disease (AD).
Technology
Engineered Targeting Chaperone Platform Technology (JUMP70) developed by SOLA to repair specific disease-causing misfolding proteins by using patient’s own chaperones
Pipeline
Ten (10) pipelines and more coming. The Flagship candidate SOL-257 is in the preclinical development for 2022 IND submission in the US.
Investment
Self-funded by an owner for 10 years, totaling $2.3M. Eisai, Mitsubishi Tanabe, and UTEC invested $8.2M. $15M Series A fundraising is in Progress.
Investors
Our Location
Contact Us
Currently no internship openings
© 2021 SOLA Biosciences